Discover trends, market shifts, and competitive outlooks for the neurological disorder drugs industry through 2025-2034 with The Business Research Company’s reliable data and in-depth research

How Has The Neurological Disorder Drugs Market Growth Evolved From 2024 To 2025, And What’s Ahead?

The market size for drugs treating neurological disorders has seen significant expansion in the recent past. It is projected to experience a follow-on growth from $84.6 billion in 2024 to $90.09 billion in 2025, with a compound annual growth rate (CAGR) of 6.5%. This growth observed in the historical period is due to factors such as enhanced animal testing yielding optimistic results, a rise in therapeutic treatments, an escalation in the incidence of neurological issues, initiatives undertaken by the government, and an increase in healthcare spending.

Predictions indicate marked escalation in the size of the neurological disorder medication market in the forthcoming years, with estimations reaching $114.65 billion in 2029, progressing at a Compound Annual Growth Rate (CAGR) of 6.2%. The anticipated expansion over the forecasted period is associated with the evolution of therapeutic alternatives and personalized treatments, increased concentration on disease-modifying solutions, rising utilization of digital biomarkers, and growing incidences of neurological disorders. Significant trends expected during this forecast period incorporate progressions in drug architecture, developments in neuroimaging, breakthroughs in genetic studies, strategic collaborations and licensing agreements, as well as the introduction of regenerative medicine.

Download a free sample to assess the report’s scope and structure:

https://www.thebusinessresearchcompany.com/sample.aspx?id=17207&type=smp

Which Major Market Drivers Are Expected to Boost the Growth Potential of the Neurological Disorder Drugs Market?

The growth of the neurological disorder drugs market is projected to be driven by the growing incidence of neurological conditions. These ailments, which are characterized by abnormalities in the brain, spinal cord or nerves’ structure, chemistry or electricity, have diverse symptoms. The surge in such disorders can be linked to global aging and increased exposure to environmental, metabolic and lifestyle hazards. The drugs used to treat these neurological disorders are crucial to their control, providing symptom relief, slowing down the progression of the disease and enhancing patients’ long-term wellbeing. For example, the Australian Institute of Health and Welfare, a government agency in Australia, forecasted in September 2024 that the population living with dementia in Australia will more than double from about 411,100 in 2023 to 849,300 by 2058, with approximately 315,500 men and 533,800 women affected. As a result, the growing incidence of neurological diseases is fuelling the expansion of the neurological disorder drugs market.

Which Segments in the Neurological Disorder Drugs Offer the Most Growth?

The neurological disorder drugs market covered in this report is segmented –

1) By Drug Class: Cholinesterase Inhibitors, N-Methyl-D-Aspartate (NMDA) Receptor Antagonists, Antiepileptic, Antipsychotic And Antidepressant, Other Drugs Classes

2) By Indication: Epilepsy, Alzheimer’s Disease, Parkinson’s Disease, Multiple Sclerosis, Cerebrovascular Disease, Other Indications

3) By Route Of Administration: Oral, Parenteral, Other Routes Of Administration

4) By Distribution Channel: Hospital Pharmacy, Retail Pharmacy, Online Pharmacy, Other Distribution Channels

5) By End-Users: Hospitals, Specialty Clinics, Homecare, Other End Users

Subsegtments:

1) By Cholinesterase Inhibitors: Donepezil, Rivastigmine, Galantamine

2) By N-Methyl-D-Aspartate (NMDA) Receptor Antagonists: Memantine, Other NMDA Receptor Antagonists

3) By Antiepileptic: Sodium Channel Blockers, GABA Enhancers, Glutamate Modulators, Other Antiepileptics

4) By Antipsychotic and Antidepressant: Risperidone, Olanzapine, SSRIs, SNRIs, Tricyclic

5) By Other Drug Classes: Dopaminergic Drugs, Alpha-2 Agonists, Immunomodulators, Other Neurological Disorder Medications

Request customized data on this market:

https://www.thebusinessresearchcompany.com/customise?id=17207&type=smp

Which Areas Are Leading Regions in the Neurological Disorder Drugs Market Expansion Across the Globe?

North America was the largest region in the neurological disorder drugs market in 2024. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the neurological disorder drugs market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East, Africa.

What Are the Key Market Trends in the Neurological Disorder Drugs Market Over the Coming Years?

Significant players in the neurological disorder drugs market are currently emphasizing on the creation of novel Ocrelizumab drug therapies. Their goal is to improve the efficiency of treatment, enhance the results for patients, and broaden the range of therapeutic choices for those suffering from multiple sclerosis. Ocrelizumab is a specialized monoclonal antibody utilized as a medicinal drug for treating multiple sclerosis (MS), a neurological disorder variant. For example, in February 2024, Roche Holding AG, a Switzerland-based pharmaceutical manufacturer, introduced Ocrevus (Ocrelizumab), a fresh disease-altering therapy (DMT) drug for the treatment of multiple sclerosis in India. Ocrevus holds the distinction of being the first and only approved DMT for both relapsing-remitting multiple sclerosis (RRMS) and primary progressive multiple sclerosis (PPMS), backed by a decade of clinical and practical data. This monoclonal antibody specifically targets CD20-positive B cells, thought to contribute to the autoimmune assault on the central nervous system in cases of multiple sclerosis (MS). Ocrevus is used to address both RRMS and PPMS, establishing it as the first medication approved for both variations of the condition. The drug is usually provided through intravenous methods every six months and has demonstrated effectiveness in minimizing disease activity and halting disability progression in clinical studies.

View the full report here:

https://www.thebusinessresearchcompany.com/report/neurological-disorder-drugs-global-market-report

What Are the Key Elements That Define the Neurological Disorder Drugs Market?

Neurological disorder drugs refer to medications used to treat disorders of the nervous system. These disorders can affect the brain, spinal cord, and nerves throughout the body. The drugs aim to manage symptoms, slow the progression of the disorder, and improve the quality of life for individuals affected.

Purchase the full report and get a swift delivery:

https://www.thebusinessresearchcompany.com/purchaseoptions.aspx?id=17207

About The Business Research Company:

With over 15000+ reports from 27 industries covering 60+ geographies, The Business Research Company has built a reputation for offering comprehensive, data-rich research and insights. Armed with 1,500,000 datasets, the optimistic contribution of in-depth secondary research, and unique insights from industry leaders, you can get the information you need to stay ahead in the game.

Get in touch with us:

The Business Research Company: https://www.thebusinessresearchcompany.com/

Americas +1 3156230293

Asia +44 2071930708

Europe +44 2071930708

Email us at info@tbrc.info

Follow us on:

LinkedIn: https://in.linkedin.com/company/the-business-research-company

YouTube: https://www.youtube.com/channel/UC24_fI0rV8cR5DxlCpgmyFQ

Global Market Model: https://www.thebusinessresearchcompany.com/global-market-model